IMUX nears pivotal Phase III readouts for vidofludimus calcium in relapsing MS
IMUX says vidofludimus calcium is nearing pivotal Phase III readouts in relapsing MS. The oral therapy targets both inflammatory and neurodegenerative mechanisms, aiming to address unmet needs in efficacy and safety.
Vidofludimus calcium is approaching pivotal phase III readouts in relapsing MS, with the program targeting both inflammatory and neurodegenerative disease mechanisms through an oral therapy that is positioned as differentiated. The program is aimed at significant commercial impact by addressing unmet needs in efficacy, safety and tolerability.